MENU

CSL managing director in the spotlight

With less than two weeks to go until the long-time managing director of blood plasma group CSL (ASX: CSL) Brian McNamee hangs up his lab coat and retires, The Australian Financial Review has reported on an outstanding tenure that saw McNamee take “CSL from a $23 million dollar government entity to a $28 billion global giant.” It is certainly an impressive feat and long-term CSL shareholders will no doubt be incredibly grateful to McNamee for creating so much shareholder value.

Biotechnology and medical device companies can be a great hunting ground for investors to sniff out a successful firm at the early stages of its technology development and then stay aboard for a long and profitable ride. Shareholders in implantable hearing device firm Cochlear (ASX: COH) and breathing device manufacturer ResMed  (ASX: RMD), like CSL shareholders, have also enjoyed outstanding returns. As the chart below shows, these three stocks have all substantially outperformed the S&P/ASX 200 Index (Index: ^AXJO) (ASX: XJO) over the past 13 years.

CSL

Source: Google Finance

Foolish takeaway

The performance at CSL shows what great management can achieve and why many of the world’s greatest investors insist on only investing in companies with management teams which they admire and trust.

Wanting to find some high-yielding ASX shares worth admiring? Get “3 Stocks for the Great Dividend Boom” in our special FREE report. Click here now to find out the names, stock symbols, and full research for our three favourite income ideas, all completely free!

More reading


Motley Fool contributor Tim McArthur has no financial interest in any company mentioned in this article.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…

Including:

The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!